Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290934 · ClinicalTrials.gov registry record · Phase 2
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
- 20
- Study locations
NCT06290934 is a Phase 2 study of Ulcerative Colitis that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 228 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06290934, a Phase 2 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.
Conditions Studied
Interventions
- DRUG GS-1427
- DRUG Placebo-to-match GS-1427
Study Locations (20)
California
- Om Research LLC - Camarillo
- VVCRD Research - Garden Grove
- 310 Clinical Research - Inglewood
- US San Diego Health System - La Jolla
- Om Research LLC - Lancaster
- UCSF Benioff Children's Hospital Oakland - Oakland
- University Of California, Davis - Sacramento
- SDG Clinical Research, LLC - San Diego
- Acclaim Clinical Research - San Diego
Florida
- Gastro Florida - Clearwater
- Best Quality Research, Inc - Hialeah
- United Research Institute LLC - Hialeah
- University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center(Drug shipment)-Research Pharmacy - Miami
- Medical Professional Clinical Research Center, Inc. - Miami
- Blessed Health Care & Research, Inc - Miami
- Alliance Clinical Research of Tampa, LLC - New Port Richey
- Digestive and Liver Center of Florida, LLC - Orlando
Colorado
- Peak Gastroenterology Associates - Colorado Springs
- Peak Gastroenterology Associates - Colorado Springs
Arizona
- Onyx Clinical Research (Clinic Location) - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06290934
The ClinicalTrials.gov registry entry for NCT06290934 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (89% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which GS-1427 is the first listed.
NCT06290934 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06290934 about?
NCT06290934 is a clinical study titled "Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis". The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to as...
What is the current status of trial NCT06290934?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2024-03-27. Estimated completion is 2028-04.
What conditions does trial NCT06290934 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06290934?
The interventions under investigation include: GS-1427 (DRUG), Placebo-to-match GS-1427 (DRUG).
Who is sponsoring clinical trial NCT06290934?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290934 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.